SK13492002A3 - Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie - Google Patents
Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie Download PDFInfo
- Publication number
- SK13492002A3 SK13492002A3 SK1349-2002A SK13492002A SK13492002A3 SK 13492002 A3 SK13492002 A3 SK 13492002A3 SK 13492002 A SK13492002 A SK 13492002A SK 13492002 A3 SK13492002 A3 SK 13492002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- lps
- coli
- lipoid
- dsm
- lipopolysaccharides
- Prior art date
Links
- 239000002158 endotoxin Substances 0.000 title claims abstract description 73
- 229920006008 lipopolysaccharide Polymers 0.000 title claims abstract description 67
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 claims description 10
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002906 microbiologic effect Effects 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 abstract description 8
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 2
- 229920001542 oligosaccharide Polymers 0.000 description 25
- 150000002482 oligosaccharides Chemical class 0.000 description 24
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 9
- 102000000589 Interleukin-1 Human genes 0.000 description 9
- 108010002352 Interleukin-1 Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 231100000284 endotoxic Toxicity 0.000 description 4
- 230000002346 endotoxic effect Effects 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 238000001030 gas--liquid chromatography Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- -1 sialic acid oligosaccharides Chemical class 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001551 total correlation spectroscopy Methods 0.000 description 2
- XLEYFDVVXLMULC-UHFFFAOYSA-N 2',4',6'-trihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=C(O)C=C1O XLEYFDVVXLMULC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VOBNSQKMDIOJTQ-UHFFFAOYSA-N 2-aminoethyl phosphono hydrogen phosphate Chemical compound NCCOP(O)(=O)OP(O)(O)=O VOBNSQKMDIOJTQ-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- BGWQRWREUZVRGI-OLLRPPRZSA-N D-glucoheptopyranose Chemical compound OC[C@H](O)[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O BGWQRWREUZVRGI-OLLRPPRZSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- YPZMPEPLWKRVLD-UHFFFAOYSA-N L-glycero-D-manno-heptose Natural products OCC(O)C(O)C(O)C(O)C(O)C=O YPZMPEPLWKRVLD-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241001523956 Parengyodontium album Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10013539A DE10013539B4 (de) | 2000-03-20 | 2000-03-20 | Lipopolysaccharide aus Escherichia coli, Verfahren zu deren Herstellung und deren Verwendungen |
| PCT/EP2001/003153 WO2001070756A2 (de) | 2000-03-20 | 2001-03-20 | Lipopolysaccharide aus escherichia coli |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK13492002A3 true SK13492002A3 (sk) | 2003-03-04 |
Family
ID=7635468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1349-2002A SK13492002A3 (sk) | 2000-03-20 | 2001-03-20 | Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6833451B2 (et) |
| EP (1) | EP1266023A2 (et) |
| JP (1) | JP2003528175A (et) |
| KR (1) | KR20030047878A (et) |
| CN (1) | CN1436245A (et) |
| AP (1) | AP2002002622A0 (et) |
| AU (2) | AU2001273899B2 (et) |
| BG (1) | BG107115A (et) |
| BR (1) | BR0109392A (et) |
| CA (1) | CA2402544A1 (et) |
| CZ (1) | CZ20023469A3 (et) |
| DE (1) | DE10013539B4 (et) |
| EA (1) | EA005217B1 (et) |
| EE (1) | EE200200537A (et) |
| HK (1) | HK1053148A1 (et) |
| HR (1) | HRP20020682A2 (et) |
| HU (1) | HUP0204540A3 (et) |
| IL (1) | IL151785A0 (et) |
| IS (1) | IS6517A (et) |
| MX (1) | MXPA02009215A (et) |
| NO (1) | NO20024480L (et) |
| NZ (1) | NZ520968A (et) |
| PL (1) | PL368447A1 (et) |
| SK (1) | SK13492002A3 (et) |
| UA (1) | UA75068C2 (et) |
| WO (1) | WO2001070756A2 (et) |
| YU (1) | YU71202A (et) |
| ZA (1) | ZA200207408B (et) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
| DE10328669B4 (de) * | 2003-06-26 | 2005-12-01 | Pharma-Zentrale Gmbh | Plasmidfreier Klon des E. coli Stammes DSM 6601 |
| WO2005051321A2 (en) * | 2003-11-25 | 2005-06-09 | Washington University | Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase |
| US20050238651A1 (en) * | 2003-11-25 | 2005-10-27 | Gurtner Gregory J | Treatment of inflammatory bowel disease |
| WO2006025995A2 (en) * | 2004-07-27 | 2006-03-09 | The Regents Of The University Of California | Compositions and methods using md-2 mutants and chimeric proteins |
| CN100354428C (zh) * | 2005-01-13 | 2007-12-12 | 丁友玲 | 隧道式干热灭菌设备测试用内毒素指示剂的制备方法 |
| EP1961823B1 (en) | 2005-11-28 | 2024-06-12 | Biomedical Research Group Inc. | Method for producing lipopolysaccharide and lipopolysaccharide |
| US9664677B2 (en) | 2010-04-19 | 2017-05-30 | Massachusetts Institute Of Technology | Polymer-nanostructure composition for selective molecular recognition |
| US20130066064A1 (en) * | 2010-05-20 | 2013-03-14 | Glaxosmithkline Biologicals S.A, | Novel process |
| CN105137073A (zh) * | 2015-08-06 | 2015-12-09 | 中国兽医药品监察所 | 牛布鲁氏菌胶体金抗体检测试纸条 |
| PL432842A1 (pl) * | 2020-02-10 | 2021-08-16 | Uniwersytet Warszawski | LPS do zastosowania w indukowaniu u osobnika tolerancji na alergeny pokarmowe wywołujące alergie pokarmowe zależne od IgE |
| AU2021235152B2 (en) * | 2020-03-13 | 2026-02-05 | Hephaistos-Pharma | Detoxified lipopolysaccharides (IPS), naturally non-toxic lps, and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19844191A1 (de) * | 1998-09-28 | 2000-03-30 | Pharma Zentrale Gmbh | Lipopolysaccharide aus Escherichia coli |
-
2000
- 2000-03-20 DE DE10013539A patent/DE10013539B4/de not_active Expired - Lifetime
-
2001
- 2001-03-20 HU HU0204540A patent/HUP0204540A3/hu unknown
- 2001-03-20 BR BR0109392-4A patent/BR0109392A/pt not_active IP Right Cessation
- 2001-03-20 JP JP2001568957A patent/JP2003528175A/ja active Pending
- 2001-03-20 YU YU71202A patent/YU71202A/sh unknown
- 2001-03-20 AP APAP/P/2002/002622A patent/AP2002002622A0/en unknown
- 2001-03-20 CZ CZ20023469A patent/CZ20023469A3/cs unknown
- 2001-03-20 PL PL01368447A patent/PL368447A1/xx unknown
- 2001-03-20 MX MXPA02009215A patent/MXPA02009215A/es unknown
- 2001-03-20 HK HK03104380.7A patent/HK1053148A1/zh unknown
- 2001-03-20 AU AU2001273899A patent/AU2001273899B2/en not_active Ceased
- 2001-03-20 WO PCT/EP2001/003153 patent/WO2001070756A2/de not_active Ceased
- 2001-03-20 EE EEP200200537A patent/EE200200537A/et unknown
- 2001-03-20 IL IL15178501A patent/IL151785A0/xx unknown
- 2001-03-20 NZ NZ520968A patent/NZ520968A/en unknown
- 2001-03-20 UA UA2002108256A patent/UA75068C2/uk unknown
- 2001-03-20 SK SK1349-2002A patent/SK13492002A3/sk unknown
- 2001-03-20 AU AU7389901A patent/AU7389901A/xx active Pending
- 2001-03-20 KR KR1020027012241A patent/KR20030047878A/ko not_active Abandoned
- 2001-03-20 US US10/239,254 patent/US6833451B2/en not_active Expired - Fee Related
- 2001-03-20 EP EP01940260A patent/EP1266023A2/de not_active Withdrawn
- 2001-03-20 HR HRP20020682 patent/HRP20020682A2/hr not_active Application Discontinuation
- 2001-03-20 CA CA002402544A patent/CA2402544A1/en not_active Abandoned
- 2001-03-20 EA EA200200997A patent/EA005217B1/ru not_active IP Right Cessation
- 2001-03-20 CN CN01806916A patent/CN1436245A/zh active Pending
-
2002
- 2002-08-21 IS IS6517A patent/IS6517A/is unknown
- 2002-09-16 ZA ZA200207408A patent/ZA200207408B/xx unknown
- 2002-09-18 BG BG107115A patent/BG107115A/bg unknown
- 2002-09-19 NO NO20024480A patent/NO20024480L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kulshin et al. | Structural characterization of the lipid A component of Pseudomonas aeruginosa wild‐type and rough mutant lipopolysaccharides | |
| Zaehringer et al. | Molecular structure of lipid A, the endotoxic center of bacterial lipopolysaccharides | |
| Sabesan et al. | Combined chemical and enzymatic synthesis of sialyloligosaccharides and characterization by 500-MHz and proton and carbon-13 NMR spectroscopy | |
| Haishima et al. | Structural investigation on the lipopolysaccharide of Escherichia coli rough mutant F653 representing the R3 core type | |
| SK13492002A3 (sk) | Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie | |
| Isshiki et al. | Isolation and characterisation of disodium (4-amino-4-deoxy-β-l-arabinopyranosyl)-(1⃗8)-(d-glycero-α-d-talo-oct-2-ulopyranosylonate)-(2⃗4)-(methyl 3-deoxy-d-manno-oct-2-ulopyranosid) onate from the lipopolysaccharide of Burkholderia cepacia | |
| KNIREL et al. | Somatic antigens of Pseudomonas aeruginosa: The structure of the O‐specific polysaccharide chain of the lipopolysaccharide from P aeruginosa O13 (Lányi) | |
| Masoud et al. | General strategy for structural analysis of the oligosaccharide region of lipooligosaccharides. Structure of the oligosaccharide component of Pseudomonas aeruginosa IATS serotype 06 mutant R5 rough-type lipopolysaccharide | |
| Rau et al. | Production and structural analysis of the polysaccharide secreted by Trametes (Coriolus) versicolor ATCC 200801 | |
| Holst et al. | Chemical structure of the lipid A of Escherichia coli J‐5 | |
| JPH06145189A (ja) | スフィンゴ糖脂質 | |
| JPWO1992012986A1 (ja) | スフィンゴ糖脂質 | |
| Molinaro et al. | Full structural characterization of Shigella flexneri M90T serotype 5 wild-type R-LPS and its Δ galU mutant: glycine residue location in the inner core of the lipopolysaccharide | |
| Rybka et al. | Determination of endotoxin by the measurement of the acetylated methyl glycoside derivative of Kdo with gas–liquid chromatography-mass spectrometry | |
| Janusch et al. | Structural and biological characterization of highly purified hepta-acyl lipid A present in the lipopolysaccharide of the Salmonella enterica sv. Minnesota Re deep rough mutant strain R595 | |
| Cox et al. | Structural analysis of the lipopolysaccharide from Vibrio cholerae serotype O22 | |
| Ieranò et al. | Against the rules: A marine bacterium, Loktanella rosea, possesses a unique lipopolysaccharide | |
| EP0704536B1 (de) | Verfahren zur Isolierung und Reinigung von nukleotidaktivierten Zuckern aus biologischen Quellen | |
| Zdorovenko et al. | Composition, structure, and biological properties of lipopolysaccharides from different strains of Pseudomonas syringae pv. atrofaciens | |
| Katzenellenbogen et al. | 3-Deoxy-octulosonic acid-containing trisaccharide fragment of an unusual core type of some Hafnia alvei lipopolysaccharides | |
| Cescutti et al. | The structure of the acidic exopolysaccharide produced by Pseudomonas “gingeri” strain Pf9 | |
| Kokoulin et al. | Partial structure and immunological properties of lipopolysaccharide from marine-derived Pseudomonas stutzeri KMM 226 | |
| CN119372085B (zh) | 一种戊糖片球菌、改性胞外多糖及其制备方法和在抗氧化剂制备中的应用 | |
| Veremeichenko et al. | Specific structural features and immunomodulatory properties of the lipopolysaccharides of Pseudomonas bacteria | |
| Kobatake et al. | Lipopolysaccharide isolated from Mycobacterium tuberculosis strain Aoyama B |